WALTHAM

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 9, 2024
FDA, CMS, Risk, SARS-CoV-2, Food, Webcast, U.S. FDA, Administration, Research and development, Pre-exposure prophylaxis, COVID-19, Patient, Immunodeficiency, Medicine, Medicare, Clinical trial, HCPCS, Vaccine

“The recent months have been incredibly productive for Invivyd.

Key Points: 
  • “The recent months have been incredibly productive for Invivyd.
  • At the beginning of April, Invivyd announced that PEMGARDA is available for purchase in the U.S. through a network of authorized specialty distributors.
  • The company will begin reporting PEMGARDA net product revenue with its second quarter 2024 financial results.
  • First Quarter 2024 Financial Results:
    Cash Position: Cash and cash equivalents were $189.4 million as of March 31, 2024.

Morphic to Participate in RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Thursday, May 9, 2024
Conditional sentence, CFO, Conference, Biotechnology

WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.

Key Points: 
  • WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.
  • A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section of Morphic’s website at www.morphictx.com .
  • An archived replay will be available on the company’s website following the conference.

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Retrieved on: 
Thursday, May 9, 2024
Cancer, Antigen, HLA, IND, PRAME, Patient, Neoplasm, TCR, Therapy

WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in the Company’s Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors. The patient, diagnosed with metastatic melanoma, was dosed with TSC-203-A0201 targeting the cancer-associated antigen PReferentially expressed Antigen in MElanoma (PRAME).

Key Points: 
  • The patient, diagnosed with metastatic melanoma, was dosed with TSC-203-A0201 targeting the cancer-associated antigen PReferentially expressed Antigen in MElanoma (PRAME).
  • “There is a lot of enthusiasm for this trial, and we are already manufacturing TCR-T products for three more patients.
  • “Customized multiplex TCR-T therapy is designed to achieve durable responses by overcoming tumor heterogeneity and resistance that develops from either target or HLA loss.
  • We look forward to sharing initial data from our solid tumor trial later this year.”

Great Elm Group Reports Fiscal 2024 Third Quarter Financial Results

Retrieved on: 
Wednesday, May 8, 2024
Sale, Tenant, SPV, Great Elm, BTS, Collection, BEACH, Conference, PALM, GEG, AUM, Cryptocurrency

PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal third quarter ended March 31, 2024.

Key Points: 
  • PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal third quarter ended March 31, 2024.
  • Great Elm collected incentive fees for the fourth consecutive quarter from GECC, totaling $0.7 million for the three months ended March 31, 2024.
  • Net loss in the quarter was driven by an approximately ($2.9) million unrealized loss on our investment in Great Elm Strategic Partnership I, LLC during the quarter.
  • Net loss in the quarter was driven by an approximately ($2.9) million unrealized loss on our investment in Great Elm Strategic Partnership I, LLC during the quarter.

Markforged Announces First Quarter 2024 Results

Retrieved on: 
Wednesday, May 8, 2024
University, Mechanical engineering, Webcast, 3D, Mechanical, Harvard Business School, Senior lecturer, Patent, District court, Judgement, MBA, GAAP, Growth

WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Markforged Holding Corporation (NYSE: MKFG) (the “Company”), the company strengthening manufacturing resiliency by enabling industrial production at the point of need, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Markforged Holding Corporation (NYSE: MKFG) (the “Company”), the company strengthening manufacturing resiliency by enabling industrial production at the point of need, today announced its financial results for the first quarter ended March 31, 2024.
  • Cash and cash equivalents were $107.9 million as of March 31, 2024 compared to $116.9 million as of December 31, 2023.
  • “While global capital expenditures on manufacturing equipment have remained challenging, we met a pivotal milestone and began shipping the FX10 in the first quarter.
  • Markforged announced the appointment of George Riedel to its Board of Directors, effective May 7, 2024.

Crane NXT, Co. Reports First Quarter Results

Retrieved on: 
Wednesday, May 8, 2024
Public expenditure, Operations security, Crane Currency, CPI, Acquisition, Cryptocurrency

WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT) ("Crane NXT" or the "Company"), a premier industrial technology company, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • For the first quarter of 2024, cash provided by operating activities was $9.5 million, compared with $35.5 million last year.
  • (Please see the Non-GAAP Financial Measures tables in this release for a detailed reconciliation of reported results to adjusted measures).
  • The Company repaid $0.7 million of its term loan facility as of March 31, 2024, with an outstanding balance of $104.3 million.
  • There is no change to the core sales growth guidance for Crane NXT's segments, CPI and Crane Currency, provided on February 14, 2024.

Imprivata provides untapped, actionable insights into access management with Enterprise Access Management Analytics

Retrieved on: 
Wednesday, May 8, 2024
Health, SSO, Product management, Investment, Organization, Risk management

WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Imprivata, the digital identity company for life- and mission-critical industries, today announced the availability of Imprivata Enterprise Access Management (formerly OneSign) Analytics , a first-of-its-kind analytics intelligence solution that provides unprecedented visibility into user access workflows.

Key Points: 
  • WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Imprivata, the digital identity company for life- and mission-critical industries, today announced the availability of Imprivata Enterprise Access Management (formerly OneSign) Analytics , a first-of-its-kind analytics intelligence solution that provides unprecedented visibility into user access workflows.
  • This is a key step in adapting Imprivata’s vision to meet the evolving operational and security needs of the healthcare industry.
  • EAM Analytics provides unparalleled insights into every access event across all modalities to identify and address security issues and optimize existing access management solutions, empowering healthcare organizations with actionable information to improve user workflows and clinician experiences.
  • “We’re thrilled to provide customers with a new analytics solution that enables them to visualize and take action on their access data without the burden of building time-consuming queries – a major component in developing a robust, optimized access management strategy,” said Zach Blunt, VP of Product Management at Imprivata.

Salary.com’ Comp XL Wins Two Lighthouse Research 2024 HR Tech Awards

Retrieved on: 
Tuesday, May 7, 2024
Kenexa, Heart, Software, Content, Culture, Acquisition, Caesars Entertainment, Lighthouse

Waltham, MA, May 07, 2024 (GLOBE NEWSWIRE) -- Salary.com, the top provider of software and data solutions for managing total compensation, has won two 2024 HR Tech Awards from Lighthouse Research & Advisory.

Key Points: 
  • Waltham, MA, May 07, 2024 (GLOBE NEWSWIRE) -- Salary.com, the top provider of software and data solutions for managing total compensation, has won two 2024 HR Tech Awards from Lighthouse Research & Advisory.
  • The Lighthouse Research & Advisory HR Tech Awards are an annual happening.
  • One of the most talked about products of the year attains the recognition it deserves.
  • The recent acquisition and incorporation of CompXL's comp planning features cements that status,” said Ben Eubanks, Chief Research Officer, Lighthouse Research & Advisory.

Cogent Biosciences Reports First Quarter 2024 Financial Results

Retrieved on: 
Tuesday, May 7, 2024
AAAAI, American Academy, Brain, Safety, Stromal cell, Mouse, PEAK, Cash, Research, HER2, GIST, ASCO, Patient, Society, AACR, APEX, Edema, G&A, Growth, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.
  • Cogent remains on track to complete enrollment in PEAK by the end of 2024 and report top-line results by the end of 2025.
  • G&A expenses include non-cash stock compensation expense of $5.0 million for the first quarter of 2024 as compared to $2.9 million for the first quarter of 2023.
  • Net Loss: Net loss was $58.3 million for the first quarter of 2024 compared to a net loss of $38.6 million for the first quarter of 2023.

Repligen Corporation to Present at Upcoming May Investor Conferences

Retrieved on: 
Tuesday, May 7, 2024
RBC, SVB Securities, RBC Capital Markets, Conference

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

Key Points: 
  • WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
  • RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15.
  • Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m.
  • Craig-Hallum’s 21st Annual Institutional Investor Conference, being held in Minneapolis on May 29.